1. Generics Bulletin
  2. >>Business
  3. >>Strategy

The Generics Bulletin Podcast: Teva, Sandoz, Sawai and US Orange Book patents

Editorial Team Discusses Strategic Moves By Major Players And US Patent Listing Debate

 
• By Dave Wallace

Generics Bulletin’s editorial team discusses the latest strategic developments for major industry players Teva, Sandoz and Sawai, as well as explaining the recent debate over US patent listings in the FDA’s Orange Book.

Generic Bulletin Podcast

This edition of the Generics Bulletin podcast sees editor Dave Wallace, deputy editor Dean Rudge and reporters Urtė Fultinavičiūtė and Adam Zamecnik discuss recent strategic moves for Teva, Sandoz and Sawai as well as controversy over US patent listings in the US Food and Drug Administration’s Orange Book.

Citeline · The Generics Bulletin Podcast: Teva, Sandoz, Sawai and US Orange Book patents

Open Media

Generics Bulletin previously covered the latest developments in Teva’s strategy in an in-depth article. (Also see "A Year After ‘Pivot To Growth’, Teva Keeps Pushing Forward With Innovative Assets" - Generics Bulletin, 13 May, 2024.)

We also previously covered Sandoz’s most recent strategic moves in biosimilars. (Also see "Sandoz ‘Surfs The Biosimilars Wave’ Despite US Natalizumab Delay" - Generics Bulletin, 8 May, 2024.)

Sawai recently reported its annual results for its financial year ended 31 March. (Also see "Sawai Narrowly Misses Annual Sales Forecast For 2023" - Generics Bulletin, 21 May, 2024.)

And a recent study shed light on US patents filed after FDA approval. (Also see "Majority Of US Patent Thickets Filed Post-FDA Approval, Study Finds" - Generics Bulletin, 16 May, 2024.)

More from Strategy

Biocon Biologics Plans To Slow Down After Five Planned Near-Term Biosimilar Launches

 
• By Urtė Fultinavičiūtė

With a lineup of five high-value biosimilars in the wings, Biocon Biologics may be more selective going forward and plans to take a one product per year approach.

Biocon Eyes Fundraising Round Amid Discussions On Merger With Biosimilars Branch

 
• By Urtė Fultinavičiūtė

As financial volatility continues in the industry, Biocon’s board is considering merging its two off-patent drug businesses.

UK-India FTA Could Offer ‘Significant Benefits’ For Generics And Biosimilars

 
• By Dave Wallace

A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

More from Business

UK-India FTA Could Offer ‘Significant Benefits’ For Generics And Biosimilars

 
• By Dave Wallace

A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.